Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Frimley Park Hospital
Frimley
GU16 7UJ


Skip to Main Content

Efficacy Study of Single Stage Breast Reconstruction in Female Participants With Mastectomy

Stopped

Open to: Female

Age: 18 Years - N/A

Medical Conditions

Mastectomy and Breast Reconstruction


This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.




The purpose of this study was to compare the efficacy of immediate single-stage post-mastectomy breast reconstruction with Strattice Reconstructive Tissue Matrix (Strattice) as compared to immediate two-stage post-mastectomy breast reconstruction where the initially placed expander was exchanged for a breast implant only, without any type of reinforcement.

The primary objective of this study is to compare the efficacy of immediate single-stage post-mastectomy breast reconstruction with Strattice™ TM, otherwise referred to as DTI as compared to immediate two-stage post-mastectomy breast reconstruction where the initially placed expander will be exchanged for a breast implant only, without any type of a reinforcement. The objective will be achieved by prospectively assessing the number of planned and unplanned post-mastectomy surgical interventions within 12 months of the mastectomy. Two-stage breast reconstruction will include the initial placement of a tissue expander in a total or partial submuscular position. In the case of partial muscle coverage, this will be without the support of any mesh or autologous flap to reinforce the lower pole. The expander will be inflated over approximately the next one to six months, and then replaced with an implant.


Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2013

Aug 2016

Interventional

Intervention Type : Procedure
Intervention Arm Group : Breast Reconstruction, Direct to Implant (DTI) with Strattice™

Intervention Type : Procedure
Intervention Arm Group : Two Stage Breast Reconstruction

You can take part if:


Inclusion Criteria: - Female 18 years or older - A candidate for both arms of the study involving immediate breast reconstruction post-skin sparing mastectomy (unilateral or bilateral) DTI with the use of Strattice™ Reconstructive Tissue Matrix (TM), 2 stage with use of Tissue Expander through exchange to Implant without support of a mesh or autologous tissue) - An American Society of Anesthesiologists (ASA) Physical Status Classification of 1 or 2 - Estimated life expectancy > 3 years - Able and willing to return for all scheduled and required study visits - Able to provide written informed consent for study participation Exclusion Criteria: - Clinically significant systemic disease, as determined by the Investigator, which could affect study participation or study results - Received neo-adjuvant, inductive chemo-therapy (except Herceptin, or other targeted therapy) within 4 weeks prior to mastectomy - Previous radiation therapy to either breast at any time - Predicted permanent implant size that is greater than or equal to 500 grams (gms), per Investigator assessment - Body mass index (BMI) <17 or > 30 - Co-morbid factors which predispose to postoperative infection, e.g. diabetes, collagen vascular disease, chronic steroid (except inhalers)/immunosuppressant use, immune deficiency, or co-existent infection - Pregnant or lactating - 3rd degree ptosis - Prior breast surgery including breast reduction, augmentation, mastopexy, quadrectomy, and partial mastectomy with reduction of the skin envelope - Prior use of a device (mesh or matrix) in the Breast - Concomitant unrelated condition of breast/chest wall/skin that, as determined by the investigator, could adversely affect the surgical outcome (e.g. significant chest wall abnormalities including pectus excavatum or pectus carinatum) - Planned autologous tissue flap in addition to prosthetic implant - Use of permanent expander implants such as Becker expanders or the Natrelle™ Permanent expander 150 - Current alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction - Currently enrolled or plans to enroll in another clinical trial unless it is: a registry, a retrospective study, a neo-adjuvant chemotherapy trial (as long as the chemotherapy regimen has been stopped 4 weeks prior to mastectomy), or a hormone/anti-hormonal therapy trial - Any of the conditions identified within the labelled contraindications, i.e. sensitivity to porcine derived products or polysorbate 20.




You may not be able to take part if:

This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Frimley Park Hospital
    Frimley
    GU16 7UJ
  • City Hospital
    Nottingham
    NG5 1PB
  • St Luke's hospital / Bradford Royal Infirmary (BRI)
    Bradford
    BD5 0NA
  • Dorset County Hospital
    Dorchester
    DT1 2JY
  • Wythenshawe Hospital UHSM NHS Foundation Trust
    Manchester
    M23 9LT


The study is sponsored by LifeCell .



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details

for Trial ID: NCT01910298

Last updated

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.